186 related articles for article (PubMed ID: 37625119)
1. Inhibiting Phosphatidylcholine Remodeling in Adipose Tissue Increases Insulin Sensitivity.
He M; Li Z; Tung VSK; Pan M; Han X; Evgrafov O; Jiang XC
Diabetes; 2023 Nov; 72(11):1547-1559. PubMed ID: 37625119
[TBL] [Abstract][Full Text] [Related]
2. Deficiency in lysophosphatidylcholine acyltransferase 3 reduces plasma levels of lipids by reducing lipid absorption in mice.
Li Z; Jiang H; Ding T; Lou C; Bui HH; Kuo MS; Jiang XC
Gastroenterology; 2015 Nov; 149(6):1519-29. PubMed ID: 26226572
[TBL] [Abstract][Full Text] [Related]
3. Lpcat3 deficiency promotes palmitic acid-induced 3T3-L1 mature adipocyte inflammation through enhanced ROS generation.
Hu J; Deng Y; Ding T; Dong J; Liang Y; Lou B
Acta Biochim Biophys Sin (Shanghai); 2022 Nov; 55(1):117-130. PubMed ID: 36331295
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Phospholipid Remodeling Modulates Insulin Sensitivity and Systemic Metabolism.
Tian Y; Mehta K; Jellinek MJ; Sun H; Lu W; Shi R; Ingram K; Friedline RH; Kim JK; Kemper JK; Ford DA; Zhang K; Wang B
Adv Sci (Weinh); 2023 Jun; 10(18):e2300416. PubMed ID: 37088778
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidylcholine acyltransferase 3 deficiency impairs 3T3L1 cell adipogenesis through activating Wnt/β-catenin pathway.
Feng C; Lou B; Dong J; Li Z; Chen Y; Li Y; Zhang X; Jiang XC; Ding T
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):834-843. PubMed ID: 29673706
[TBL] [Abstract][Full Text] [Related]
6. Targeting phospholipid remodeling pathway improves insulin resistance in diabetic mouse models.
Tian Y; Lu W; Shi R; McGuffee R; Lee R; Ford DA; Wang B
FASEB J; 2023 Nov; 37(11):e23251. PubMed ID: 37823674
[TBL] [Abstract][Full Text] [Related]
7. Substrate preferences of a lysophosphatidylcholine acyltransferase highlight its role in phospholipid remodeling.
Kazachkov M; Chen Q; Wang L; Zou J
Lipids; 2008 Oct; 43(10):895-902. PubMed ID: 18781350
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase.
Zhao Y; Chen YQ; Bonacci TM; Bredt DS; Li S; Bensch WR; Moller DE; Kowala M; Konrad RJ; Cao G
J Biol Chem; 2008 Mar; 283(13):8258-65. PubMed ID: 18195019
[TBL] [Abstract][Full Text] [Related]
9. Macrophage Lysophosphatidylcholine Acyltransferase 3 Deficiency-Mediated Inflammation Is Not Sufficient to Induce Atherosclerosis in a Mouse Model.
Jiang H; Li Z; Huan C; Jiang XC
Front Cardiovasc Med; 2018; 5():192. PubMed ID: 30705887
[TBL] [Abstract][Full Text] [Related]
10. Lysophospholipid acylation modulates plasma membrane lipid organization and insulin sensitivity in skeletal muscle.
Ferrara PJ; Rong X; Maschek JA; Verkerke AR; Siripoksup P; Song H; Green TD; Krishnan KC; Johnson JM; Turk J; Houmard JA; Lusis AJ; Drummond MJ; McClung JM; Cox JE; Shaikh SR; Tontonoz P; Holland WL; Funai K
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33591957
[TBL] [Abstract][Full Text] [Related]
11. Identification of Hepatic Lysophosphatidylcholine Acyltransferase 3 as a Novel Target Gene Regulated by Peroxisome Proliferator-activated Receptor δ.
Singh AB; Liu J
J Biol Chem; 2017 Jan; 292(3):884-897. PubMed ID: 27913621
[TBL] [Abstract][Full Text] [Related]
12. Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis.
Tian Y; Jellinek MJ; Mehta K; Seok SM; Kuo SH; Lu W; Shi R; Lee R; Lau GW; Kemper JK; Zhang K; Ford DA; Wang B
Hepatology; 2024 Apr; 79(4):882-897. PubMed ID: 36999536
[TBL] [Abstract][Full Text] [Related]
13. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion.
Rong X; Wang B; Dunham MM; Hedde PN; Wong JS; Gratton E; Young SG; Ford DA; Tontonoz P
Elife; 2015 Mar; 4():. PubMed ID: 25806685
[TBL] [Abstract][Full Text] [Related]
14. The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease.
Lagrost L; Masson D
Curr Opin Lipidol; 2022 Jun; 33(3):193-198. PubMed ID: 35165232
[TBL] [Abstract][Full Text] [Related]
15. Adipose tissue peroxisomal lipid synthesis orchestrates obesity and insulin resistance through LXR-dependent lipogenesis.
Kleiboeker B; He A; Tan M; Lu D; Hu D; Liu X; Goodarzi P; Hsu FF; Razani B; Semenkovich CF; Lodhi IJ
Mol Metab; 2024 Apr; 82():101913. PubMed ID: 38458567
[TBL] [Abstract][Full Text] [Related]
16. A novel assay for measuring recombinant human lysophosphatidylcholine acyltransferase 3 activity.
Du X; Hu J; Zhang Q; Liu Q; Xiang X; Dong J; Lou B; He S; Gu X; Cao Y; Li Y; Ding T
FEBS Open Bio; 2019 Oct; 9(10):1734-1743. PubMed ID: 31376210
[TBL] [Abstract][Full Text] [Related]
17. Small Intestine but Not Liver Lysophosphatidylcholine Acyltransferase 3 (Lpcat3) Deficiency Has a Dominant Effect on Plasma Lipid Metabolism.
Kabir I; Li Z; Bui HH; Kuo MS; Gao G; Jiang XC
J Biol Chem; 2016 Apr; 291(14):7651-60. PubMed ID: 26828064
[TBL] [Abstract][Full Text] [Related]
18. Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet.
Bourgeois T; Jalil A; Thomas C; Magnani C; Le Guern N; Gautier T; Pais de Barros JP; Bergas V; Choubley H; Mazzeo L; Menegaut L; Josiane Lebrun L; Van Dongen K; Xolin M; Jourdan T; Buch C; Labbé J; Saas P; Lagrost L; Masson D; Grober J
J Lipid Res; 2021; 62():100013. PubMed ID: 33518513
[TBL] [Abstract][Full Text] [Related]
19. Caspase-independent hepatocyte death: A result of the decrease of lysophosphatidylcholine acyltransferase 3 in non-alcoholic steatohepatitis.
Kakisaka K; Suzuki Y; Fujiwara Y; Suzuki A; Kanazawa J; Takikawa Y
J Gastroenterol Hepatol; 2019 Jul; 34(7):1256-1262. PubMed ID: 30160786
[TBL] [Abstract][Full Text] [Related]
20. Liver-specific overexpression of LPCAT3 reduces postprandial hyperglycemia and improves lipoprotein metabolic profile in mice.
Cash JG; Hui DY
Nutr Diabetes; 2016 Apr; 6(4):e206. PubMed ID: 27110687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
